Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-high trading volume on Monday . Approximately 311,976 shares traded hands during trading, a decline of 45% from the previous session’s volume of 562,807 shares.The stock last traded at $3.91 and had previously closed at $3.91.

Analysts Set New Price Targets

A number of research firms have weighed in on IVA. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Truist Financial started coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. Finally, Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $16.56.

Inventiva Stock Performance

The company has a fifty day simple moving average of $4.52 and a 200-day simple moving average of $5.32.

Institutional Investors Weigh In On Inventiva

Large investors have recently made changes to their positions in the company. Creative Planning acquired a new position in Inventiva in the 2nd quarter worth approximately $32,000. Virtu Financial LLC acquired a new stake in Inventiva during the 4th quarter valued at $60,000. XTX Topco Ltd acquired a new stake in Inventiva during the 4th quarter valued at $84,000. Cerity Partners LLC purchased a new stake in shares of Inventiva in the fourth quarter valued at $93,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the third quarter valued at $116,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.